Prevalence of Congenital Long QT Syndrome and Acquired QT Prolongation in a Hospital Cohort

Long QT Syndrome Clinical Trial

Official title:

Prevalence of Congenital Long QT Syndrome and Acquired QT Prolongation in a Hospital Cohort

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03544918
• Other study ID #: REK 2013/1090
• Status: Completed
• Start date: June 2015
• Est. completion date: November 6, 2020

Study information

• Verified date: November 2020
• Source: Sykehuset Telemark
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The Long QT syndrome is associated with potentially life-threatening cardiac arrhythmias as ventricular tachycardia (Torsade de pointes) as well as ventricular fibrillation, and might lead to syncope as well as sudden cardiac death (1). Good results have been achieved by treating patient at risk with beta blockers and implantable cardiac defibrillator (ICD). It is therefore important to diagnose the condition as early as possible as the disease is treatable (2).

Prolonged QT duration might also be induced by the intake of numerous pharmaceutical substances, as well as with electrolyte disturbances, which also increases the risk of life-threatening cardiac arrhythmias. Furthermore, congenital LQTS can arise from mutations in one of at least 13 different genes. Many of these genes encode proteins which are constituents of ion channels. The genetically defined long QT syndrome has autosomal dominant (Romano Ward Syndrome) or autosomal recessive (Jervell and Lange-Nielsen Syndrome) inheritance.

In this study we are using the hospital ECG database obtained with the GE Marquette 12SL ECG Analysis Program® at Telemark Hospital Skien recorded between March 2004 and April 2014. This database stores approximately 200 000 ECG recordings from 60 000 unique patients.

By using the search algorithm in the MUSE ECG database, 2398 recordings have been be identified from 1603 patients where the corrected QT time is longer than 500 ms, and QRS is less than 120 ms.

ECG recordings with QT intervals longer than 500 ms represents less than 1% of the population (5). Individuals having these recordings are selected for extensive clinical follow up. The patients will be offered the opportunity to have genetic analysis performed in order to distinguish between inherited or acquired long QT syndrome. The appropriate treatment will be initiated according to guidelines for patients with inherited QT syndrome. For patients with aquired long QT syndrome substitution of unfavourable pharmacotherapy or correction of electrolytes shall be performed in order to reduce their risk of cardiac arrhythmias.

A T wave morphology score gives independent prognostic information useful for risk stratification. The purpose of this substudy is to examine if the T wave morphology score applied on the 1531 patients ECGs with QTc >500 ms, has independent prognostic value in this cohort.

Description:

2. PURPOSE OF THE STUDY

The study has the intention to:

• Identify patients with inherited LQTS in order to give them optimal treatment.

• To identify patients with acquired QT prolongation in order to possibly correct electrolyte disorders and therapeutically prescriptions in order to minimize the chance of life-threatening arrhythmias.

• To analyse to what extend a specific reason for QT prolongation can be found in patients with heart rate adjusted QT prolongation, or to which extend the QT prolongation without syncope, or family history of sudden cardiac death, is an unspecific finding.

• To analyse time dependent risk of patients with QT prolongation related to underlying disease

• To analyse to what extend genetic variations might predispose for acquired QT prolongation.

• To compare life expectancy of patients with QT prolongation related to case control patients with out QT prolongation.

• To implement rapid reaction on newly diagnosed QT prolongation, and follow up of survival after implementation of improved care.

• To examine if the T wave morphology score applied on patients ECGs with QTc >500 ms, has independent prognostic value in this cohort.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1536
• Est. completion date: November 6, 2020
• Est. primary completion date: November 6, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

QT time in EKG more Tham 500 ms -

Exclusion Criteria:

Patient refuses to be a part of the study registry

Related Conditions & MeSH terms

• Long QT Syndrome
• Syndrome

Locations

Country	Name	City	State
Norway	Sykehuset Telemark	Skien	Telemark

Sponsors (2)

Lead Sponsor	Collaborator
Sykehuset Telemark	Oslo University Hospital

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	survival	Death certificate information from national register	2004-2014
Secondary	comorbidity data from hospital database Genetic defects data	Data extracted from hospital notes	2004-2014